Peer Reviewed Publications

Powell LC, et al. Alginate oligosaccharides enhance the antifungal activity of nystatin against candidal biofilms. Front. Cell. Infect. Microbiol. 2023, 13:1122340. doi: 10.3389/fcimb.2023.1122340.


Stokniene J, et al. Alginate oligosaccharides enhance diffusion and activity of colistin in a mucin-rich environment. Sci Rep, 2022 Mar 23;12(1):4986. doi: 10.1038/s41598-022-08927-1.


Fischer R, et al. Evaluating the alginate oligosaccharide (OligoG) as a therapy for Burkholderia cepacia complex cystic fibrosis lung infection. J. Cyst. Fibros. 2022.


Weiser R, et al. Implementation of microbiota analysis in clinical trials for cystic fibrosis lung infection: Experience from the OligoG phase 2b clinical trials. J Microbiol. Methods 2021, 181;


Oakley J, et al. Phenotypic and genotypic adaptations in Pseudomonas aeruginosa biofilms following long-term exposure to an alginate oligomer therapy. mSphere 2021 Jan 20; 6(1): e01216-20. doi: 10.1128/mSphere.01216-20.


Van Koningsbruggen-Rietschel S, et al. Inhaled dry powder alginate oligosaccharide (OligoG) in cystic fibrosis: A randomized, double-blind, placebo controlled cross-over Phase 2B study. ERJ Open Res 2020; 0: 00132-2020 [].


Tøndervik A, et al. Exploiting mannuronan C-5 epimerases in commercial alginate production. Marine Drugs 2020, 18, 565; doi:10.3390/md18110565


Stokniene J, et al. Bi-functional alginate oligosaccharide-polymyxin conjugates for improved treatment of multidrug-resistant Gram-negative bacterial infections. Pharmaceutics 2020, 12, 1080; doi:10.3390/pharmaceutics12111080.


Pritchard MF et al. Mucin structural interactions with an alginate oligomer mucolytic in cystic fibrosis sputum. Vib. Spectrosc. 2019 July, 103:102932.


Jack AA, et al. Cellulose nanofibril formulations incorporating low molecular weight alginate oligosaccharide modify bacterial biofilm development. Biomacromolecules. 2019 Aug 12;20(8):2953-2961. doi: 10.1021/acs.biomac.9b00522. Epub 2019 Jul 11.


Powell LC, et al. Targeted Disruption of the Extracellular Polymeric Network of Pseudomonas aeruginosa Biofilms by Alginate Oligosaccharides. NPJ Biofilms and Microbiomes 2018 Jun 29;4:13. doi: 10.1038/s41522-018-0056-3. eCollection 2018.


Jack AA, et al. Alginate Oligosaccharide-Induced Modification of the lasI-lasR and rhlI-rhlR Quorum-Sensing Systems in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 2018 Apr 26; 62(5). doi: 10.1128/AAC.02318-17.


Rye PD, et al. Alginate oligomers and their use as active pharmaceutical drugs. In “Alginates and their Biomedical Applications” Springer Series in Biomaterials Science and Engineering (Vol. eds. Rehm H.A. and Moradali F.), 2018, Vol 11. Published Springer Singapore.


Pritchard MF, et al. Alginate Oligosaccharides modify hyphal infiltration of Candida albicans in an In Vitro Model of Invasive Human Candidosis. J. Appl Micro. 2017, Sep;123(3):625-636.


Tøndervik A, et al. Alginate oligomers inhibit growth of bacteria causing bovine mastitis and potentiate the activity of antibiotics commonly used for treatment of the disease. J. Adv. Dairy Res. 2017 5:186. doi: 10.4172/2329-888X.1000186


Pritchard MF, et al. A low molecular weight alginate oligosaccharide disrupts pseudomonal microcolony formation and enhances antibiotic effectiveness. Antimicrobial Agents and Chemotherapy 2017 Aug 24;61(9).


Pritchard MF, et al. The antimicrobial effects of the alginate oligomer OligoG CF-5/20 are independent of direct bacterial cell membrane disruption. Scientific Reports. 2017, Mar 31;7:44731. doi: 10.1038/srep44731.


Ermund A, et al. OligoG CF-5/20 normalizes cystic fibrosis mucus by chelating calcium. Clin Exp Pharmacol Physiol. 2017 44, 639-647.


Vitko M, et al. A novel guluronate oligomer improves intestinal transit and survival in cystic fibrosis mice. J Cyst Fibros. 2016 Nov 15(6):745-751.


Pritchard MF, et al. A New Class of Safe Oligosaccharide Polymer Therapy To Modify the Mucus Barrier of Chronic Respiratory Disease. Mol Pharm. 2016 Mar 7;13(3):863-72. doi: 10.1021/acs.molpharmaceut.5b00794. Epub 2016 Feb 16.


Hengzhuang W, et al. OligoG CF-5/20 disruption of mucoid Pseudomonas aeruginosa biofilm in a murine lung infection model. Antimicrob Agents Chemother. 2016 60, 2620-2626.


Nordgård CT, et al. Alterations in mucus barrier function and matrix structure induced by guluronate oligomers. Biomacromolecules. 2014 Jun 9;15(6):2294-300.


Tøndervik A, et al. Alginate oligosaccharides inhibit fungal cell growth and potentiate the activity of antifungals against Candida and Aspergillus spp. PLoS One. 2014 Nov 19;9(11):e112518.


Powell LC, et al. A nanoscale characterization of the interaction of a novel alginate oligomer with the cell surface and motility of Pseudomonas aeruginosa. Am J Respir Cell Mol Biol. 2014 Mar;50(3):483-92.


Roberts JL, et al. An in vitro study of alginate oligomer therapies on oral biofilms. J Dent. 2013 Oct;41(10):892-9.


Powell LC, et al. The effect of alginate oligosaccharides on the mechanical properties of Gram-negative biofilms. Biofouling. 2013;29(4):413-21.


Sletmoen M, et al. Oligoguluronate induced competitive displacement of mucin–alginate interactions: relevance for mucolytic function. Soft Matter, 2012, 8, 8413.


Khan S, et al. Overcoming drug resistance with alginate oligosaccharides able to potentiate the action of selected antibiotics. Antimicrob Agents Chemother. 2012 Oct;56(10):5134-41.


Nordgård CT, Draget KI. Oligosaccharides as modulators of rheology in complex mucus systems. Biomacromolecules. 2011 Aug 8;12(8):3084-90.